Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Altace Co-Promotion Lawsuit Spurs Question About King's Ability To Launch Nebivolol

This article was originally published in The Pink Sheet Daily

Executive Summary

An investment firm says Wyeth's lawsuit alleging King failed to meet its detailing obligations for Altace raises "concern" that King will lack the manpower needed to promote Mylan's beta blocker. Mylan says the King acquisition is the best strategy for maximizing nebivolol.

You may also be interested in...



Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says

King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace

Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says

King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace

Mylan/King Merger, GSK's Fluarix Expected To Highlight Oct. 28 Earnings Calls

Also reporting on Oct. 28 are Elan, ImClone and Medco. Final heavy week of quarterly pharma earnings updates include Oct. 27 reports by P&G, Merck KGaA and Novo Nordisk.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel